# An independent evaluation unit for surgical robots and AI, paid on evidence

Source: https://onco.cc/ideas/idea-fund-surgical-ai-robotics-evaluation/  
OnCo record `idea-fund-surgical-ai-robotics-evaluation` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hospitals buy multi-million-dollar surgical robots and AI tools with little proof they help patients. An independent body would run the comparative trials, and payers would only pay premiums for what is shown to work.

## Summary

A publicly-funded evaluation unit, analogous to a health technology assessment body but with the capacity to sponsor randomised and registry-based comparisons, for surgical robotics, intraoperative AI (anatomy recognition, margin prediction, skill assessment) and autonomous surgical functions in cancer surgery. Reimbursement premiums for these technologies would be conditional on participation in unit-led evaluations, with results published. Robotic surgery has diffused for two decades with few randomised trials, and surgical AI is following the same path; the drug world's requirement for evidence before payment is absent here.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: An evaluation unit with conditional-payment leverage generates randomised or high-quality comparative evidence for at least ten surgical robotic or AI applications within four years and leads to at least two adoption decisions being reversed or restricted on the basis of that evidence.
- Rationale: Where randomised trials of robotic surgery have been done (ROLARR for rectal cancer, RAZOR for cystectomy) they showed no oncological advantage and much higher cost; those trials were run without any systematic mechanism. Coverage with evidence development has made trials happen for cardiac devices and proton therapy.
- Proposed test: Establish the unit, link premium reimbursement of two technologies to enrolment in its comparative studies, and measure evidence generated and adoption changes over four years.
- Maturity: speculative
- Actor: payer

## Sources

- Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015): https://doi.org/10.1016/S1470-2045(15)00223-5

## Connected records

- ideas: [A video-based surgical quality registry linking assessed skill to cancer outcomes](https://onco.cc/ideas/idea-fund-surgical-video-registry/), [Coverage-with-evidence registries for MR-guided and adaptive radiotherapy](https://onco.cc/ideas/idea-fund-adaptive-radiotherapy-evidence/), [Mandatory staged registries for new surgical techniques before wide adoption](https://onco.cc/ideas/idea-fund-device-technique-registry/)
- technologies: [Fluorescence-guided surgery](https://onco.cc/technologies/fluorescence-guided-surgery/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/)
- companies: [Intuitive Surgical](https://onco.cc/companies/intuitive-surgical/)
- bottlenecks: [AI that is built but not validated or deployed](https://onco.cc/bottlenecks/b-ai-validation/), [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/)
- key papers: [Global cancer surgery: delivering safe, affordable, and timely cancer surgery](https://onco.cc/key-papers/paper-sullivan-lancet-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-surgical-ai-robotics-evaluation.json